Brief: Beyondspring Pharmaceuticals Receives Complete Response Letter From FDA For Plinabulin New Drug Application For Prevention Of Chemotherapy-Induced Neutropenia
BeyondSpring says U.S. FDA declined to approve neutropenia prevention drug
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:55 AM
BeyondSpring Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Beyondspring Says First Patient Treated In Phase 2 Study With Plinabulin Combined With Nivolumab + Ipilimumab
U.S. RESEARCH ROUNDUP- Denali Therapeutics, Steven Madden, Vail Resorts
U.S. STOCKS ON THE MOVE-Edesa Biotech, Cognyte, Zivo Bioscience, automakers
U.S. STOCKS ON THE MOVE-Verastem, Tesla, Synlogic, U.S. banks
Brief: Beyondspring Announces Positive Final Phase 3 DUBLIN-3 Data With The Plinabulin/Docetaxel Combination Vs Docetaxel Alone
Brief: Beyondspring Presents Positive Data On Plinabulin From Its Neutropenia Prevention Program
U.S. RESEARCH ROUNDUP- Caremax, Equinix, Motorola Solutions
BeyondSpring Inc reports results for the quarter ended in June - Earnings Summary
Brief: Beyondspring Announces Second Quarter 2021 Financial Results
U.S. RESEARCH ROUNDUP-Blade Air Mobility, Hyzon Motors, Kadmon Holdings
BeyondSpring Inc expected to post a loss of 48 cents a share - Earnings Preview
BeyondSpring Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Beyondspring Announces Late-Breaking Oral Presentation Of Final Phase 3 Data With The Plinabulin/Docetaxel Combination In Non-Small Cell Lung Cancer
BeyondSpring Inc expected to post a loss of 48 cents a share - Earnings Preview
BeyondSpring jumps on deal to commercialize cancer drug in China